Does neurotensin mediate the effects of antipsychotic drugs?

Biological Psychiatry

Volumn 46, Issue 3, 1999, Pages 340-351

  Kinkead, Becky ^a   Binder, Elisabeth B ^a   Nemeroff, Charles B ^a  

^a Lab of Neuropsychopharmacology   (United States)

Author keywords

Clinical efficacy; Extrapyramidal side effect; Schizophrenia

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; MESSENGER RNA; NEUROLEPTIC AGENT; NEUROMEDIN N; NEUROTENSIN; NEUROTENSIN RECEPTOR ANTAGONIST;

ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN TISSUE; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROGNOSIS; RAT; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEURONS; NEUROTENSIN; NUCLEUS ACCUMBENS; RECEPTORS, NEUROTENSIN; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 0032783157     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00070-0     Document Type: Review

References (119)

1. Asan E. The cathecholaminergic innervation of the rat amygdala. Adv Anat Embryol Cell Biol. 142:1998;1-118.
2. Azzi M., Betancur C., Sillaber I., Spanagel R., Rostène W., Bérod A. Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems. J Neurochem. 71:1998;1158-1167.
3. Bachus S.E., Kleinman J.E. The neuropathology of schizophrenia. J Clin Psychiatry. 57:1996;72-83.
4. Bayer V.E., Towle A.C., Pickel V.M. Vesicular and cytoplasmic localization of neurotensin-like (NTLI) in neurons postsynaptic to terminals containing NTLI and/or tyrosine hydroxylase in the rat central nucleus of the amygdala. J Neuroscience Res. 30:1991;398-413.
5. Binder E., Owens M.J., Kilts C.D., Nemeroff C.B. Involvement of neurotensin in latent inhibition. Soc Neurosci Abst. 24:1998;82.8.
6. Bissette G., Nemeroff C.B. The neurobiology of neurotensin. Bloom F.E., Kupfer D.J. Neuropsychopharmacology, The Fourth Generation of Progress. 1995;573-582 Raven Press, New York.
7. Bissette G., Nemeroff C.B., Decker M.W., Kizer J.S., Agid Y., Javoy-Agid F. Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease. Ann Neurol. 17:1985;324-328.
8. Bissette G., Nemeroff C.B., Loosen P.T., Prange A.J. Jr, Lipton M.A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature. 262:1976;607-609.
9. Björklund A, Lindvall O (1984): Dopamine containing systems in the CNS. Handbook of Chemical Neuroanatomy 2 Classical transmitters in the CNS, part 1. Amsterdam: Elsevier, pp 55-122.
10. Blaha C.D., Coury A., Fibiger H.C., Phillips A.G. Effects of neurotensin on dopamine release and metabolism in the rat striatum and nucleus accumbens Cross-validation using in vivo voltammetry and microdialysis . Neuroscience. 34:1990;699-705.
11. Blaha C.D., Phillips A.G. Pharmacological evidence for common mechanisms underlying the effects of neurotensin and neuroleptics on in vivo dopamine efflux in the rat nucleus accumbens. Neuroscience. 49:1992;867-877.
12. Bligh-Glover W., Jaskiw G., Vrtunski B., Ubogy D., Meltzer H. 5HT-2 antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophr Res. 15:1995;153-154.
13. Bolden-Watson C., Watson M.A., Murray K.D., Isackson P.J., Richelson E. Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J Neurochem. 61:1993;1141-1143.
14. Boudin H., Pélaprat D., Rostène W., Beaudet A. Cellular distribution of neurotensin receptors in rat brain Immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor . J Comp Neurol. 373:1996;76-89.
15. Breslin N.A., Suddath R.L., Bissette G., Nemeroff C.B., Lowrimore P., Weinberger D.R. CSF concentrations of neurotensin in schizophrenia An investigation of clinical and biochemical correlates . Schizophr Res. 12:1994;35-41.
16. Brouard A., Pélaprat D., Dana C., Vial M., Lhiaubet A.-M., Rostène W. Mesencephalic dopaminergic neurons in primary culture express functional neurotensin receptors. J Neurosci. 12:1992;1409-1415.
17. Brun P., Steinberg R., Le Fur G., Soubrié P. Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens. J Neurochem. 64:1995;2073-2079.
18. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B., et al. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386:1996;91-94.
19. Chapman M.A., See R.E., Bissette G. Neurotensin increases extracellular striatal dopamine levels in vivo. Neuropeptides. 22:1992;175-183.
20. Delle Donne K.T., Sesack S.R., Pickel V.M. Ultrastructural immunocytochemical localization of neurotensin and the dopamine D2 receptor in the rat nucleus accumbens. J Comp Neurol. 371:1996;552-566.
21. Deutch A.Y., Lee M.C., Iadarola M.J. Regionally specific events of atypical antipsychotic drugs on striatal Fos expression The nucleus accumbens shell as a locus of antipsychotic action . Mol Cell Neurosci. 3:1992;332-341.
22. Diaz J., Levesque D., Griffon N., Lammers C.H., Martres M.P., Sokoloff P., et al. Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci. 6:1994;1384-1387.
23. Dilts R.P., Kalivas P.W. Autoradiographic localization of mu-opiod and neurotensin receptors within the mesolimbic dopamine system. Brain Res. 488:1989;311-327.
24. Drumheller A.D., Gagne M.A., St-Pierre S., Jolicoeur F.B. Effects of neurotensin on regional brain concentrations of dopamine, serotonin and their main metabolites. Neuropeptides. 15:1990;169-178.
25. Dubuc I., Costentin J., Terranova J.P., Barnouin M.C., Soubrié P., Le Fur G., et al. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br J Pharmacol. 112:1994;352-354.
26. Dunn L.A., Atwater G.E., Kilts C.D. Effects of antipsychotic drugs on latent inhibition Sensitivity and specificity of an animal behavioral model of clinical drug action . Psychopharmacol. 112:1993;315-323.
27. Emson P.C., Horsfield P.M., Goedert M., Rossor M.N., Hawkes C.H. Neurotensin in human brain Regional distribution and effects of neurological illness . Brain Res. 347:1985;239-244.
28. Ervin G.N., Birkemo L.S., Nemeroff C.B., Prange A.J. Jr. Neurotensin blocks certain amphetamine-induced behaviors. Nature. 291:1981;73-76.
29. Febvret A., Berger B., Gaspar P., Verney C. Further indication that distinct dopaminergic subsets project to the rat cerebral cortex lack of colocalization with neurotensin in the superficial dopaminergic fields of the anterior cingulate, motor, retrosplenial and visual cortices . Brain Res. 547:1991;37-52.
30. Feifel D., Minor K.L., Dulawa S., Swerdlow N.R. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res. 760:1997;80-84.
31. Feifel D., Reza T.L., Robeck S.L. Pro-dopamine effects of neurotensin on sensorimotor gating deficits. Peptides. 18:1997;1457-1460.
32. Ferraro L., Antonelli T., O'Connor W.T., Fuxe K., Soubrié P., Tanganelli S. The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release Functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop . J Neurosci. 18:1998;6977-6989.
33. Garver D.L., Bissette G., Yao J.K., Nemeroff C.B. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am J Psychiatry. 148:1991;484-488.
34. Gaspar P., Berger B., Febvret A. Neurotensin innervation of the human cerebral cortex Lack of colocalization with catecholamines . Brain Res. 530:1990;181-195.
35. Govoni S., Hong J.S., Yang H.Y.-T., Costa E. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. J Pharmacol Exp Ther. 215:1980;413-417.
36. Grace A.A., Bunney B.S., Moore H., Todd C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 20:1997;31-37.
37. Grace A.A., Moore H., O'Donnell P. The modulation of corticoaccumbens transmission by limbic afferents and dopamine A model for the pathophysiology of schizophrenia . Adv Pharmacol (New York). 42:1998;721-724.
38. Gully D., Labeeuw B., Boigegrain R., Oury-Donat F., Bachy A., Poncelet M., et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther. 280:1997;802-812.
39. 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain. Proc Natl Acad Sci U S A. 83:1986;6203-6207.
40. Hoebel B.G. Neurotransmitters in the control of feeding and its rewards Monoamines, opiates, and brain-gut peptides . Res Publ Assoc Res Nerv Men Dis. 62:1984;15-38.
41. Hökfelt T., Everitt B.J., Theodorsson-Norheim E., Goldstein M. Occurrence of neurotensin-like immunoreactivity in subpopulations of hypothalamic, mesencephalic and medullary catecholamine neurons. J Comp Neurol. 222:1984;543-559.
42. Huang W., Hanson G.R. Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems. Eur J Pharmacol. 332:1997;15-21.
43. Jennes L., Stumpf W.E., Kalivas P.W. Neurotensin Topographical distribution in the rat brain by immunohistochemistry . J Comp Neurol. 210:1982;211-224.
44. Jolas T., Aghajanian G. Neurotensin and the serotonergic system. Prog Neurobiol. 52:1997;455-468.
45. Jolicoeur F.B., DeMichele G., Barbeau A., St-Pierre S. Neurotensin affects hyperactivity but not stereotypy induced by pre and post synaptic dopaminergic stimulation. Neurosci Biobehav Rev. 7:1983;385-390.
46. Kahn R., Davidson M. Serotonin, dopamine and their interaction in schizophrenia. Psychopharmacology. 112:(Suppl 1):1993;S1-S4.
47. Kalivas P.W., Duffy P. Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J Neurosci. 10:1990;2940-2949.
48. Kalivas P.W., Miller J.S. Neurotensin neurons in the ventral tegmental area project to the medial nucleus accumbens. Brain Res. 300:1984;157-160.
49. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 153:1996;466-476.
50. Kilts C.D., Anderson C.M., Bissette G., Ely T.D., Nemeroff C.B. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem Pharmacol. 37:1988;1547-1554.
51. Kinkead B., Binder E., Owens M.J., Nemeroff C.B. Interaction between the neurotensin receptor antagonist SR142948A and dopamine agonists in prepulse inhibition of the acoustic startle response. Soc Neuroscience Abst. 24:1998;765.6.
52. Kinkead B., Nemeroff C.B. The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system. J Clin Psychiatry. 55:1994;30-32.
53. Laitinen K., Crawley J.N., Mefford I.N., de Witte P. Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens. Brain Res. 523:1990;342-346.
54. Lambert P.D., Gross R., Nemeroff C.B., Kilts C.D. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. Ann N Y Acad Sci. 757:1995;377-389.
55. Le Moine C., Bloch B. Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens comparison with the D1 and D2 dopamine receptor . Neuroscience. 73:1996;131-143.
56. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage A potential animal model of schizophrenia . Neuropsychopharmacology. 9:1993;67-75.
57. Lubow R., Moore A. Latent inhibition The effect of non reinforced pre-exposure to the conditioned stimulus . J Comp Physiol Psychol. 52:1959;415-419.
58. Luttinger D., King R.A., Sheppard D., Strupp J., Nemeroff C.B., Prange A.J. Jr. The effect of neurotensin on food consumption in the rat. Eur J Pharmacol. 81:1982;499-503.
59. Luttinger D., Nemeroff C.B., King R.A., Ervin G.N., Prange A.J. Jr. The effect of injection of neurotensin into the nucleus accumbens on behaviors mediated by the mesolimbic dopamine system in the rat. Chronister R.B., DeFrance J.F. The Neurobiology of the Nucleus Accumbens. 1981;322-332 Haer Inst. Electrophysiology Res, Brunswick, ME.
60. Luttinger D., Nemeroff C.B., Prange A.J. Jr. The effects of neuropeptides on discrete-trial conditioned avoidance responding. Brain Res. 237:1982;183-192.
61. Mai J.K., Triepel J., Metz J. Neurotensin in the human brain. Neuroscience. 22:1987;499-524.
62. Mandell A.J., Owens M.J., Selz K.A., Morgan W.N., Shlesinger M.F., Nemeroff C.B. Mode matches in hydrophobic free energy eigenfunctions predict peptide-protein interactions. Biopolymers. 46:1998;89-101.
63. Mazella J., Zsurger N., Navarro V., Chabry J., Kaghad M., Caput D., et al. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem. 273:1998;26273-26276.
64. Merchant K.M., Dobie D.J., Filloux F.M., Totzke M., Aravagiri M., Dorsa D.M. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J Pharmacol Exp Ther. 271:1994;460-471.
65. Merchant K.M., Dobner P.R., Dorsa D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J Neurosci. 12:1992;652-663.
66. 3-neurotensin . Neuroscience. 22:1987;525-536.
67. Myers B., Levant B., Bissette G., Nemeroff C.B. Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment. Brain Res. 575:1992;325-328.
68. Nemeroff C.B. Neurotensin Perchance an endogenous neuroleptic? Biol Psychiatry. 15:1980;283-302.
69. Nemeroff C.B., Bissette G., Prange A.J. Jr, Loosen P.T., Barlow T.S., Lipton M.A. Neurotensin Central nervous system effects of a hypothalamic peptide . Brain Res. 128:1977;485-496.
70. Nemeroff C.B., Bissette G., Widerlöv E., Beckmann H., Gerner R., Manberg P.J., et al. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome. J Neuropsychiatry Clin Neurosci. 1:1989;16-20.
71. Nemeroff C.B., Luttinger D., Hernandez D.E., Mailman R.B., Mason G.A., Davis S.D., et al. Interactions of neurotensin with brain dopamine systems Biochemical and behavioral studies . J Pharmacol Exp Ther. 225:1983;337-345.
72. Nemeroff C.B., Youngblood W.W., Manberg P.J., Prange A.J. Jr, Kizer J.S. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science. 221:1983;972-975.
73. Nicot A., Rostène W., Bérod A. Neurotensin receptor expression in the rat forebrain and midbrain A combined in situ hybridization and receptor radioautography study . J Comp Neurol. 341:1994;407-419.
74. Nicot A., Rostène W., Bérod A. Differential expression of neurotensin receptor mRNA in the dopaminergic cell groups of the rat diencephalon and mesencephalon. J Neurosci Res. 40:1995;667-674.
75. Osbahr A.J.D., Nemeroff C.B., Luttinger D., Mason G.A., Prange A.J. Jr. Neurotensin-induced antinociception in mice Antagonism by thyrotropin-releasing hormone . J Pharmacol Exp Ther. 217:1981;645-651.
76. Osbahr A.J.D., Nemeroff C.B., Manberg P.J., Prange A.J. Jr. Centrally administered neurotensin Activity in the Julou-Courvoisier muscle relaxation test in mice . Eur J Pharmacol. 54:1979;299-302.
77. Palacios J.M., Kuhar M.J. Neurotensin receptors are located on dopamine-containing neurons in rat midbrain. Nature (London). 294:1981;587-589.
78. Pennartz C.M.A., Groenewegen H.J., Lopes D.A., Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles An integration of behavioral, electrophysiological and anatomical data . Prog Neurobiol. 42:1994;719-761.
79. Quirion R., Rowe W.B., Lapchak P.A., Araujo D.M., Beaudet A. Distribution of neurotensin receptors in mammalian brain. What it is telling us about its interactions with other neurotransmitter systems. Ann N Y Acad Sci. 668:1992;109-119.
80. Quirion R., Welner S., Gauthier S., Bedard P. Neurotensin receptor binding sites in monkey and human brain Autoradiographic distribution and effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment . Synapse. 1:1987;559-566.
81. Radke J.M., MacLennan A.J., Beinfeld M.C., Bissette G., Nemeroff C.B., Vincent S.R., et al. Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat. Brain Res. 480:1989;178-183.
82. Radke J.M., Owens M.J., Ritchie J.C., Nemeroff C.B. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions. Proc Natl Acad Sci U S A. 95:1998;11462-11464.
83. Rivest R., Jolicoeur F.B., Marsden C.A. Neurotensin causes a greater increase in the metabolism of dopamine in the accumbens than in the striatum in vivo. Neuropharmacol. 30:1991;25-33.
84. Roberts G.W., Ferrier I.N., Lee Y., Crow T.J., Johnstone E.C., Owens D.G., et al. Peptides, the limbic lobe and schizophrenia. Brain Res. 288:1983;199-211.
85. Roberts G.W., Woodhams P.L., Polak J.M., Crow T.J. Distribution of neuropeptides in the limbic system of the rat The amygdaloid complex . Neuroscience. 7:1982;99-131.
86. Santucci V., Gueudet C., Steinberg R., Le Fur G., Soubrié P. Involvement of cortical neurotensin in the regulation of rat meso-cortico-limbic dopamine neurons Evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade . Synapse. 26:1997;370-380.
87. Sanz B., Exposito I., Mora F. Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. Neuroreport. 4:1993;1194-1196.
88. Sarrieau A., Javoy-Agid F., Kitabgi P., Dussaillant M., Vial M., Rosselin G. Characterization and autoradiographic distribution of neurotensin binding sites in the human brain. Brain Res. 348:1985;375-380.
89. Schotte A., Leysen J.E. Autoradiographic evidence for the localization of high affinity neurotensin binding sites on dopaminergic nerve terminals in the nigrostriatal and mesolimbic pathways in rat brain. J Chem Neuroanat. 2:1989;253-257.
90. Seeman P. Receptor selectivities of atypical neuroleptics. Meltzer H.Y. Novel Antipsychotic Drugs. 1992;145-154 Raven Press, New York.
91. Seroogy K., Ceccatelli S., Schalling M., Hökfelt T., Frey P., Walsh J., et al. A subpopulation of dopaminergic neurons in rat ventral mesencephalon contain both neurotensin and cholecystokinin. Brain Res. 455:1988;88-98.
92. Seroogy K.B., Mehta A., Fallon J.H. Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon Projections to forebrain . Exp Brain Res. 68:1987;277-289.
93. Sharma R.P., Janicak P.G., Bissette G., Nemeroff C.B. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorders. Am J Psychiatry. 154:1997;1019-1021.
94. Shibata K., Yamada K., Furukawa T. Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice. Psychopharmacology. 91:1987;288-292.
95. Snijders R., Kramarcy N.R., Hurd R.W., Nemeroff C.B., Dunn A.J. Neurotensin induces catalepsy in mice. Neuropharmacol. 21:1982;465-468.
96. Stoessl A.J. Effects of neurotensin in a rodent model of tardive dyskinesia. Neuropharmacology. 34:1995;457-462.
97. Stoessl A.J., James K.A., Napier B.J. The neurotensin antagonist SR 48692 fails to modify the behavioral responses to a dopamine D1 receptor agonist in the rat. Neuropharmacol. 36:1997;93-99.
98. Stowe ZN, Landry JC, Tang Z, Owens MJ, Nemeroff CB (1999): The electrophysiological effects of neurotensin on spontaneously active type II neurons in the nucleus accumbens: An in vivo study. J Neurosci Submitted.
99. Stowe Z.N., Nemeroff C.B. The electrophysiological actions of neurotensin in the central nervous system. Life Sci. 49:1991;987-1002.
100. Studler J.-M., Kitabgi P., Tramu G., Hervé D., Glowinski J., Tassin J.-P. Extensive colocalization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides. 11:1988;95-100.
101. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry. 51:1994;139-154.
102. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull. 24:1998;285-301.
103. Swerdlow N.R., Koob G.F. Dopamine, schizophrenia, mania and depression Toward a unified hypothesis of cortico-striato-pallido-thalamic function . Behav Brain Sci. 10:1987;197-245.
104. Szigethy E., Beaudet A. Correspondence between high affinity 125I-neurotensin binding sites and dopaminergic neurons in the rat substantia nigra and ventral tegmental area. A combined radioautographic and immunocytochemical light microscopic study. J Comp Neurol. 279:1989;128-137.
105. Szigethy E., Quirion R., Beaudet A. Distribution of 125I-neurotensin binding sites in human forebrain comparison with the localization of acetylcholinesterase . J Comp Neurol. 297:1990;487-498.
106. Tanaka K., Masu M., Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron. 4:1990;847-854.
107. Tanganelli S., O'Connor W.T., Ferraro L., Bianchi C., Beani L., Ungersted U., et al. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience. 60:1994;649-657.
108. Uhl G.R. Distribution of neurotensin and its receptor in the central nervous system. Ann N Y Acad Sci. 400:1982;132-149.
109. Uhl G.R., Kuhar M.J. Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra. Nature. 309:1984;350-352.
110. Von Euler G., van der Ploeg I., Fredholm B.B., Fuxe K. Neurotensin decreases the affinity of dopamine D2 binding by a G protein-independent mechanism. J Neurochem. 56:1991;178-183.
111. Weinberger D.R., Lipska B.K. Cortical maldevelopment, antipsychotic drugs, and schizophrenia A search for a common ground . Schizophr Res. 67:1995;87-110.
112. Weiner I., Feldon J. The switching model of latent inhibition An update of neural substrates . Behav Brain Res. 88:1997;11-25.
113. Wolf S.S., Hyde T.M., Saunders R.C., Herman M.M., Weinberger D.R., Kleinman J.E. Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects. J Neural Trans Gen Sect. 102:1995;55-65.
114. Woulfe J., Beaudet A. Neurotensin terminals form synapses primarily with neurons lacking detectable tyrosine hydroxylase immunoreactivity in the rat substantia nigra and ventral tegmental area. J Comp Neurol. 321:1992;163-176.
115. Yang C.R., Mogenson G.J. Electrophysiological responses of neurons in the nucleus accumbens to hippocampal stimulation and the attenuation of the excitatory responses by the mesolimbic dopaminergic system. Brain Res. 324:1984;69-84.
116. Yeomans J.S. Role of tegmental cholinergic neurons in dopamine activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology. 12:1994;3-16.
117. Zahm D.S. Neurotensin-immunoreactive neurons in the ventral striatum of the adult rat Ventromedial caudate-putamen, nucleus accumbens and olfactory tubercle . Neurosci Letts. 81:1987;41-47.
118. Zahm D.S., Brog J.S. On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience. 50:1992;751-767.
119. Zech M., Roberts G.W., Bogerts B., Crow T.J., Polak J.M. Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea An immunohistochemical study . Acta Neuropathol. 71:1986;259-266.